NEW YORK (TheStreet) - Today we provide a post-earnings scorecard for seven of the companies we profiled pre-earnings last week. Three had post-earnings gains of 5.2% to 7.5% from the closes in their pre-earnings profile and four had losses between 3.4% and 8.9%.
We crunch the numbers to help you decide whether or not to buy weakness to value levels or to sell strength to risky levels. Check out our charts on page 2 to help you make buy and sell decisions.
($30.33, up 7.1% since May 5): Beat analysts' earnings per share estimates by 12 cents, earning 59 cents. The stock traded to a multiyear intraday high at $30.36 on Monday. The weekly chart is positive but overbought, with its five-week modified moving average at $28.17. Monthly and semiannual value levels are $28.37 and $26.27, respectively, with a weekly pivot at $30.07 and annual risky level at $35.50.
($10.89, down 5.1% since May 7): Missed analysts' EPS estimates by 52 cents, reporting a loss of 38 cents. The stock stayed below its 200-day simple moving average at $11.81 on May 8, trading as low as $10.21 on May 9. The weekly chart is negative, with its five-week MMA at $11.49 and the 200-week SMA at $10.38. Monthly and annual value levels are $10.38 and $6.92, respectively, with a quarterly pivot at $10.95, and semiannual and weekly risky levels at $12.28 and $12.30, respectively.
($70.10, up 7.5% since May 7): Beat analysts' EPS estimates by 6 cents, earning 55 cents. The stock dipped to $63.00 on May 9, holding its 200-day SMA at $63.33 then rebounded sharply to as high as $70.46 on Monday. Buying weakness to one of the five key moving averages is one of our buy-and-trade options to consider, given a positive weekly chart. The weekly chart is positive with its five-week MMA at $67.93. Weekly and quarterly value levels are $63.82 and $59.15, respectively, and monthly and semiannual risky levels at $71.88 and $74.37, respectively.
($42.45, down 4.5% since May 5): Matched analysts' EPS estimates, earning 45 cents. The stock popped to $46.50 on May 7, then fell to $41.46 on May 9, below its 200-day SMA at $42.60. The weekly chart is negative but oversold, with its five-week MMA at $45.97. Weekly and semiannual value levels are $41.02 and $40.43, respectively, with annual and quarterly risky levels at $44.44 and $55.05, respectively.
($15.32, down 8.9% since May 6): Matched analysts' EPS estimates, earning 15 cents. The stock traded as low as $14.86 on May 9. The weekly chart is negative but oversold, with its five-week MMA at $16.43. A quarterly value level lags at $7.50, with weekly and monthly risky levels at $15.93 and $18.98, respectively.
($147.34, down 3.4% since May 7): Beat analysts' EPS estimates by 4 cents, earning $1.68. The stock traded as low as $141.93 on May 9, then rebounded to as high as $148.76 on Monday. The weekly chart is negative, with its five-week MMA at $153.50 and its 200-week SMA at $147.27. We have a quarterly pivot at $147.32, with weekly and annual risky levels at $149.16 and $156.84, respectively.
($63.67, up 5.2% since May 6): Beat analysts' EPS estimates by 19 cents, earning 55 cents. The stock traded to an all-time intraday high at $64.16 on May 12, above my monthly risky level, which is now a pivot at $62.59. The weekly chart is positive but overbought, with its five-week MMA at $60.28. Weekly and quarterly value levels are $62.06 and $54.80, respectively.